The CFTR modulator Elexacaftor/Tezacaftor/Ivacaftor (ETI) shows markedly enhanced pulmonary function and reduced exacerbation frequency in people with CF (PwCF).1, 2, 3 Consequently, this improvement in pulmonary function and number of exacerbations reduced the LTx indication in PwCF.4 Here, CFTR is linked to cystic fibrosis.